secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monopar Therapeutics (MNPR)
CIK:        0001645469
Form:       8-K
Filed at:   2024-06-10T23:59:59+00:00
Accession:  0001437749-24-019747
Event type: other_material
Sentiment:  positive
Materiality: 0.40
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monopar presents preclinical uPAR-targeted radiopharma data at SNMMI; Phase 1 trial ongoing
--------------------------------------------------------------------------------

- Data show robust tumor uptake of MNPR-101-Zr in triple-negative breast, colorectal, and pancreatic cancer mouse models.
- Construct optimized for higher tumor uptake and stability with minimal bone and healthy tissue accumulation.
- First-in-human Phase 1 imaging/dosimetry trial in advanced cancer patients recently initiated led by Prof. Rodney Hicks.
- Trial details available on ClinicalTrials.gov under identifier NCT06337084.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645469/000143774924019747/0001437749-24-019747-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645469/000143774924019747/mnpr20240608c_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-019747

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer